1. Home
  2. CNEY vs GRI Comparison

CNEY vs GRI Comparison

Compare CNEY & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

N/A

Current Price

$0.51

Market Cap

2.9M

Sector

Industrials

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$1.86

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNEY
GRI
Founded
2009
2018
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
3.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
CNEY
GRI
Price
$0.51
$1.86
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $18.50
AVG Volume (30 Days)
★ 89.0K
33.1K
Earning Date
02-17-2027
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.31
$0.18
52 Week High
$2.63
$64.12

Technical Indicators

Market Signals
Indicator
CNEY
GRI
Relative Strength Index (RSI) 54.03 56.71
Support Level $0.36 $1.71
Resistance Level $0.55 $2.66
Average True Range (ATR) 0.05 0.14
MACD 0.01 0.03
Stochastic Oscillator 80.85 67.44

Price Performance

Historical Comparison
CNEY
GRI

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: